Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients

Kassamali, Bina; Kus, Kylee J.B.; Min, Michelle; Villa-Ruiz, Camila; Cobos, Gabriela; Merola, Joseph F.; Vleugels, Ruth Ann; Mazori, Daniel R.; LaChance, Avery

doi:10.1016/j.jdin.2021.03.007

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our case adds to the growing evidence that TNF-α inhibition may be an important and effective modality of treatment for the otherwise recalcitrant silicone granulomas. 2,8–10 As in the case of our patient, TNF-α inhibitors may be safer and more effective therapies than either cyclosporine or MMF. Thus, consideration should be given to initiating a TNF-α inhibitor for recalcitrant silicone granulomas before other immunomodulatory therapies.…”

Section: Discussionmentioning

confidence: 59%

“…Options include local and systemic steroids, tetracycline antibiotics, hydroxychloroquine, 5-fluorouracil, and isotretinoin. 8 Surgical management is difficult and not recommended due to the tendency of silicone to migrate and cause scarring which may be more distressing than original presenting concern of granulomatous inflammation. 9 The interferon-γ modulator, imiquimod, has been utilized, as well as tumour necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A case of recalcitrant silicone granuloma treated with adalimumab: A case report

Silverberg

Cyrenne

Croitoru

et al. 2022

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Liquid silicone is a relatively inexpensive injectable used for soft tissue augmentation. Injection of silicone is associated with a risk of delayed granuloma formation associated with elevated levels of tumour necrosis factor-α. We report a case of recalcitrant silicone granulomas following facial injections of silicone successfully treated with tumour necrosis factor-α blockade. Our case, as well as previous reports, demonstrates the effectiveness of this therapy for the treatment of foreign body granulomas from due to silicone.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Introductionmentioning

confidence: 99%

A case of recalcitrant silicone granuloma treated with adalimumab: A case report

Silverberg

Cyrenne

Croitoru

et al. 2022

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…1 Despite well-established associations between silicone injection and granuloma formation, current evidence-based management guidelines are limited. 2 , 3 The current guidelines by the American Society of Dermatologic Surgery recommend “intralesional injections of 5-FU (5-fluorouracil) mixed with triamcinolone at monthly intervals” for the treatment of silicone granulomas, with low certainty of evidence. 3 We aimed to characterize treatments and associated outcomes for silicone granulomas following silicone injection.…”

mentioning

confidence: 99%

“… 4 Many cases trialed combinations of both single and multiple treatment modalities, particularly in refractory cases. 2 …”

mentioning

confidence: 99%

Management of silicone granuloma: A systematic review

et al. 2023

View full text Add to dashboard Cite

Dermatological care of gender‐diverse patients in Australia

Wong,

Harrington,

Stevenson

2024

Aust J Dermatology

View full text Add to dashboard Cite

In recent years, there has been an increasing recognition of the unique healthcare needs of gender‐diverse patients in Australia. With the continuous growth of referrals to gender health services, there is an increased demand for specialised dermatological care. There is still a significant knowledge gap and a lack of guidelines specifically tailored to this patient group. In this article, we will provide a brief overview of the journey of Transgender and Gender Diverse (TGD) individuals as they embark on psychological and pharmacologic treatment for gender dysphoria in Australia. We endeavour to contribute to the existing body of knowledge by examining the evidence surrounding the treatment of skin, hair and nail issues for TGD patients. This article will outline how dermatologists can assist in the care of the gender‐diverse patient. Although puberty blockade (stage 1 treatments) has minimal dermatological impact, gender‐affirming pharmacotherapy (stage 2 treatments) can lead to many dermatological issues including acne, patterned hair loss (PHL) and dermatitis. The dermatologist may also play a role in stage 3 treatments which include surgical or procedural interventions for gender affirmation.

show abstract

Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients

Cited by 4 publications

References 6 publications

A case of recalcitrant silicone granuloma treated with adalimumab: A case report

A case of recalcitrant silicone granuloma treated with adalimumab: A case report

Management of silicone granuloma: A systematic review

Dermatological care of gender‐diverse patients in Australia

Contact Info

Product

Resources

About